Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) Invested Capital: 2019-2025

Historic Invested Capital for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $25.9 million.

  • Eton Pharmaceuticals' Invested Capital rose 28.83% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $54.2 million for FY2024, which is 160.05% up from last year.
  • Eton Pharmaceuticals' Invested Capital amounted to $25.9 million in Q3 2025, which was down 3.10% from $26.7 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Invested Capital high stood at $54.4 million for Q1 2025, and its period low was $16.3 million during Q1 2023.
  • Over the past 3 years, Eton Pharmaceuticals' median Invested Capital value was $21.1 million (recorded in 2023), while the average stood at $27.2 million.
  • Its Invested Capital has fluctuated over the past 5 years, first dropped by 29.97% in 2022, then surged by 165.39% in 2025.
  • Eton Pharmaceuticals' Invested Capital (MRQ) stood at $22.9 million in 2021, then dropped by 19.35% to $18.5 million in 2022, then rose by 12.97% to $20.9 million in 2023, then skyrocketed by 160.05% to $54.2 million in 2024, then plummeted by 52.24% to $25.9 million in 2025.
  • Its last three reported values are $25.9 million in Q3 2025, $26.7 million for Q2 2025, and $54.4 million during Q1 2025.